Hoe verhoudt NOTV's PS Ratio zich tot zijn concurrenten?

NOTV is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.5x).

Hoe verhoudt NOTV's PS Ratio zich tot andere bedrijven in de US Life Sciences industrie?

NOTV is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Life Sciences industry average (3.7x).

Wat is NOTV's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

NOTV is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Wat is de reële prijs van NOTV als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

NOTV ($1.78) is trading below our estimate of [[fair value]] ($35.76)

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Inotiv (Nasdaq:NOTV) - Aandelenkoers, Nieuws & Analyse

NOTV Overzicht aandelen

Inotiv, Inc. levert niet-klinische en analytische diensten voor het ontdekken en ontwikkelen van medicijnen aan de farmaceutische industrie en medische hulpmiddelen.

Over het bedrijf

NOTV fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Trading at 95% below our estimate of its fair value

Trading at good value compared to peers and industry

Risicoanalyse

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($46M)

Volatile share price over the past 3 months compared to the US market

Inotiv, Inc. Concurrenten

IsoPlexis

NasdaqGS:ISO

US$30.3m

Bionano Genomics

NasdaqCM:BNGO

US$27.0m

Rapid Micro Biosystems

NasdaqCM:RPID

US$47.2m

Seer

NasdaqGS:SEER

US$116.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inotiv
Historische aandelenkoersen
Huidige aandelenkoers	US$1.78
52 Week Hoogtepunt	US$11.42
52 Week Laag	US$1.23
Bèta	3.4
11 maand verandering	-7.53%
3 maanden verandering	4.71%
1 Jaar Verandering	2.89%
33 jaar verandering	-96.60%
5 jaar verandering	-66.16%
Verandering sinds IPO	-78.42%

Recent nieuws en updates

Recent updates

Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

Apr 26

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Mar 19

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Feb 13

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Dec 18

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Dec 13

Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization

May 25

Inotiv: Leading Mid-Market CRO Ups Its Game

Feb 07

Rendement voor aandeelhouders

	NOTV	US Life Sciences	US Markt
7D	-2.2%	2.2%	-1.6%
1Y	2.9%	17.9%	30.8%

Rendement versus industrie: NOTV underperformed the US Life Sciences industry which returned 17.9% over the past year.

Rendement versus markt: NOTV underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is NOTV's price volatile compared to industry and market?
NOTV volatility
NOTV Average Weekly Movement	11.2%
Life Sciences Industry Average Movement	7.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: NOTV's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: NOTV's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1974	2,005	Bob Leasure	www.inotivco.com

Inotiv, Inc. levert niet-klinische en analytische diensten voor het ontdekken en ontwikkelen van medicijnen aan de farmaceutische industrie en de sector voor medische apparatuur. Het bedrijf is actief via twee segmenten: Discovery and Safety Assessment (DSA) en Research Models and Services (RMS). Het DMS-segment produceert wetenschappelijke instrumenten voor biowetenschappelijk onderzoek en de bijbehorende software voor gebruik door farmaceutische bedrijven, universiteiten, onderzoekscentra van de overheid en medische onderzoeksinstellingen onder de BASi-productlijn van de onderneming.

Inotiv, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Inotiv zich tot de beurswaarde?
NOTV fundamentele statistieken
Marktkapitalisatie	US$46.29m
Inkomsten(TTM)	-US$99.22m
Inkomsten(TTM)	US$501.06m

0.1x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is NOTV overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NOTV resultatenrekening (TTM)
Inkomsten	US$501.06m
Kosten van inkomsten	US$388.00m
Brutowinst	US$113.06m
Overige uitgaven	US$212.28m
Inkomsten	-US$99.22m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.82
Brutomarge	22.56%
Nettowinstmarge	-19.80%
Schuld/Eigen Vermogen Verhouding	210.0%

Hoe presteerde NOTV op de lange termijn?

Bekijk historische prestaties en vergelijking

NOTV Overzicht aandelen

Beloningen

Risicoanalyse

Inotiv, Inc. Concurrenten

NasdaqGS:ISO

US$30.3m

NasdaqCM:BNGO

US$27.0m

NasdaqCM:RPID

US$47.2m

NasdaqGS:SEER

US$116.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 70% to US$4.67

Inotiv, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 70% to US$4.67

Inotiv, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024

Inotiv, Inc. announced delayed 10-Q filing

Inotiv, Inc. to Report Q2, 2024 Results on May 10, 2024

Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

New major risk - Share price stability

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Consensus EPS estimates upgraded to US$1.15 loss

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Price target increased by 22% to US$15.50

An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc. (NasdaqCM:NOTV).

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024

Inotiv, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Inotiv, Inc., Annual General Meeting, Mar 14, 2024

Consensus EPS estimates fall by 18%

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Chief Operating Officer recently bought US$150k worth of stock

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Full year 2023 earnings: EPS misses analyst expectations

Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Inotiv, Inc. to Report Q4, 2023 Results on Dec 11, 2023

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Inotiv, Inc. Announces Changes to Its Board Composition

Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million.

Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million.

New minor risk - Market cap size

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inotiv, Inc. Revises Earnings Guidance for the Full Year 2023

Inotiv, Inc. to Report Q3, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Price target decreased by 12% to US$15.06

Inotiv, Inc.(NasdaqCM:NOTV) dropped from Russell Small Cap Comp Value Index

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inotiv, Inc. Confirms Revenue Guidance for the Fiscal Year 2023

Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?

Price target increased by 91% to US$17.17

Inotiv, Inc. Reiterates Financial Guidance for the Fiscal Year Ending September 30, 2023

Inotiv, Inc. Reports Goodwill Impairment Charges for the First Quarter Ended December 31, 2022

Inotiv, Inc. to Report Q1, 2023 Results on Feb 13, 2023

Inotiv, Inc., Annual General Meeting, Mar 16, 2023

Inotiv, Inc. Announces Board Changes

Inotiv, Inc. Provides Revenue Guidance for the First Quarter and Second Quarter to Fourth Quarter and Earnings Guidance for the Full Year Fiscal 2023

Inotiv, Inc. to Report Q4, 2022 Results on Jan 10, 2023

Inotiv, Inc. announced delayed annual 10-K filing

Inotiv, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S

Inotiv, Inc. to Report Q4, 2022 Results on Dec 12, 2022

Price target decreased to US$50.33

Price target decreased to US$50.33

Bronstein, Gewirtz & Grossman, LLC Notifies Investors That A Class Action Lawsuit Has Been Filed Against Inotiv, Inc

Inotiv, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2022

Law Offices of Howard G. Smith Files Lawsuit Against Inotiv, Inc

Inotiv, Inc. to Report Q3, 2022 Results on Aug 10, 2022